0001104659-24-007066.txt : 20240126 0001104659-24-007066.hdr.sgml : 20240126 20240126113320 ACCESSION NUMBER: 0001104659-24-007066 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240124 FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lisicki Robert CENTRAL INDEX KEY: 0001779614 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40598 FILM NUMBER: 24565514 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zura Bio Ltd CENTRAL INDEX KEY: 0001855644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-247-0520 MAIL ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: JATT Acquisition Corp DATE OF NAME CHANGE: 20210407 4 1 tm244212-4_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-24 0 0001855644 Zura Bio Ltd ZURA 0001779614 Lisicki Robert C/O ZURA BIO LIMITED 1489 W. WARM SPRINGS RD. #110 HENDERSON NV 89014 0 1 0 0 See Remarks 0 Stock options 3.98 2024-01-24 4 A 0 1000000 0 A 2034-01-24 Class A Ordinary Shares 1000000 1000000 D Consists of options to purchase 1,000,000 Class A Ordinary Shares. The vesting for 600,000 of 1,000,000 shares began on January 8, 2024 and would vest over a period of four years, with 1/4 to be vested on 01/08/2025, and thereafter 1/48 on a monthly basis. The vesting for 400,000 of 1,000,000 shares shall begin on the date of Mr. Lisicki's promotion and shall vest over a period of four years, with 1/4 to be vested on the first anniversary of the promotion date, and thereafter 1/48 on a monthly basis. President, Chief Operating Officer /s/ Robert Lisicki 2024-01-26